BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 15059147)

  • 1. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
    Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z; Yang R
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
    Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
    Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura].
    Tanai C; Iki S; Nakahara F; Iijima K; Usuki K; Kuwana M; Urabe A
    Rinsho Ketsueki; 2004 Nov; 45(11):1181-6. PubMed ID: 15609684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
    Aggarwal A; Catlett JP
    South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
    Carbone J; Escudero A; Mayayo M; Ballesteros M; Perez-Corral A; Sanchez-Ramon S; Sarmiento E; Micheloud D; Fernandez-Cruz E
    Ann N Y Acad Sci; 2005 Jun; 1051():666-71. PubMed ID: 16127007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
    Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
    Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
    Vianelli N; Galli M; de Vivo A; Intermesoli T; Giannini B; Mazzucconi MG; Barbui T; Tura S; Baccaranion M;
    Haematologica; 2005 Jan; 90(1):72-7. PubMed ID: 15642672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
    Julia A; Kovaleva L; Loria S; Alberca I; Hernandez F; Sandoval V; Sierra J; Vidaller A; Ayguasanosa J; Carretero M
    Transfus Med; 2009 Oct; 19(5):260-8. PubMed ID: 19747289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
    Latifzadeh SZ; Entezari V
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F
    Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.